Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3870533 | 1.00 | BACE1 (0.36) | BACE1ALDH1A1HSD17B10CYP2A6HPGD | |
| SCHEMBL618853 | 0.95 | BACE1 (0.39) | BACE1ALDH1A1HSD17B10CYP2A6HPGD | |
| SCHEMBL445102 | 0.91 | ALDH1A1 (0.41) | BACE1ALDH1A1HSD17B10CYP2A6HPGD | |
| SCHEMBL6880077 | 0.91 | ALDH1A1 (0.41) | BACE1ALDH1A1HSD17B10CYP2A6HPGD | |
| SCHEMBL27629739 | 0.91 | ALDH1A1 (0.41) | BACE1ALDH1A1HSD17B10CYP2A6HPGD | |
| SCHEMBL18832483 | 0.86 | ALDH1A1 (0.39) | BACE1ALDH1A1HSD17B10CYP2A6HPGD | |
| SCHEMBL1371612 | 0.85 | ALDH1A1 (0.46) | BACE1ALDH1A1HSD17B10CYP2A6HPGD | |
| SCHEMBL9957984 | 0.84 | NOTUM (0.52) | ALDH1A1HSD17B10MAPK1 | |
| SCHEMBL9770283 | 0.84 | PTGS2 (0.41) | HPGDPTGS2 | |
| SCHEMBL9958265 | 0.84 | NOTUM (0.52) | ALDH1A1HSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210078934-A1 | CHARGE-TRANSPORTING VARNISH | NISSAN CHEMICAL CORPORATION (JP) | 2021-03-18 | — | — | US | disclosed |
| US-10923662-B2 | Fluoroalkylfluorene derivatives | LOMOX LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| EP-3731290-A1 | CHARGE-TRANSPORTING VARNISH | Nissan Chemical Corporation (JP) | 2020-10-28 | — | — | EP | disclosed |
| EP-3131898-B1 | FLUOROALKYLFLUORENE DERIVATIVES | LOMOX LTD (GB) | 2020-03-18 | — | — | EP | disclosed |
| EP-2896678-B1 | Liquid crystal display | MERCK PATENT GMBH (DE) | 2018-10-17 | — | — | EP | disclosed |
| US-10084137-B2 | Fluoroalkylfluorene derivatives | LOMOX LIMITED (GB) | 2018-09-25 | — | — | US | disclosed |
| US-20180261771-A1 | FLUOROALKYLFLUORENE DERIVATIVES | LOMOX LIMITED (GB) | 2018-09-13 | — | — | US | disclosed |
| US-20180195003-A1 | PROCESS FOR THE STABILISATION OF LIQUID CRYSTAL MEDIA | MERCK PATENT GMBH (DE) | 2018-07-12 | — | — | US | disclosed |
| EP-3317373-A1 | PROCESS FOR THE STABILISATION OF LIGUID CRYSTAL MEDIA | Merck Patent GmbH (DE) | 2018-05-09 | — | — | EP | disclosed |
| US-9835890-B2 | Liquid crystal display | MERCK PATENG GMBH (DE) | 2017-12-05 | — | — | US | disclosed |
| EP-3131898-A1 | FLUOROALKYLFLUORENE DERIVATIVES | Lomox Limited (GB) | 2017-02-22 | — | — | EP | disclosed |
| US-20170033290-A1 | FLUOROALKYLFLUORENE DERIVATIVES | LOMOX LIMITED (GB) | 2017-02-02 | — | — | US | disclosed |
| WO-2017001036-A1 | PROCESS FOR THE STABILISATION OF LIGUID CRYSTAL MEDIA | MERCK PATENT GMBH (DE) | 2017-01-05 | — | — | WO | disclosed |
| US-9478744-B2 | High molecular compound, method for producing same, and light-emitting element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| WO-2015159098-A1 | FLUOROALKYLFLUORENE DERIVATIVES | LOMOX LIMITED (GB) | 2015-10-22 | — | — | WO | disclosed |
| US-20150205158-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| EP-2896678-A1 | Liquid crystal display | Merck Patent GmbH (DE) | 2015-07-22 | — | — | EP | disclosed |
| EP-2647655-A1 | HIGH MOLECULAR COMPOUND, METHOD FOR PRODUCING SAME, AND LIGHT-EMITTING ELEMENT | Sumitomo Chemical Company Limited (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130248778-A1 | HIGH MOLECULAR COMPOUND, METHOD FOR PRODUCING SAME, AND LIGHT-EMITTING ELEMENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-09-26 | — | — | US | disclosed |
| US-6936189-B2 | Cyclic tertiary amine compound and organic electroluminescent device containing the compound | CHISSO CORPORATION (JP) | 2005-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10084137-B2 | Fluoroalkylfluorene derivatives | FLNB, AFF2, EFHD2 | BACE1 2166/4885ALDH1A1 88/4885HSD17B10 2283/4885 |
| US-20170033290-A1 | FLUOROALKYLFLUORENE DERIVATIVES | FLNB, AFF2, EFHD2 | BACE1 2166/4885ALDH1A1 88/4885HSD17B10 2283/4885 |
| US-10923662-B2 | Fluoroalkylfluorene derivatives | FLNB, AFF2, EFHD2 | BACE1 2166/4885ALDH1A1 88/4885HSD17B10 2283/4885 |
| US-20180261771-A1 | FLUOROALKYLFLUORENE DERIVATIVES | FLNB, AFF2, EFHD2 | BACE1 2166/4885ALDH1A1 88/4885HSD17B10 2283/4885 |
| US-20210078934-A1 | CHARGE-TRANSPORTING VARNISH | SLC43A1, SLC7A5, SLC38A7 | BACE1 3277/4885ALDH1A1 967/4885HSD17B10 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.